










Meetinghe International OrganizationTfor the Study of Inflammatory
Bowel Diseases (IOIBD) is the only
global organization devoted to the
study of and management of the in-
flammatory bowel diseases (IBDs),
namely, Crohn’s disease and ulcerative
colitis. Membership is composed of
physician-scientists who have estab-
lished expertise in these diseases. The
organization hosts an annual meeting
and a number of working groups
addressing issues of the epidemiology
of IBD, diet and nutrition, and the
development and use of treatments for
IBD. There are currently 89 members
of IOIBD representing 26 different
countries. The organization has taken
particular interest in the coronavirus
disease-2019 (COVID-19) pandemic
and how it may affect the IBD patient
population. This document summa-
rizes the results of 2 recent virtual
meetings of the group and subsequent





In December 2019, health officials
in Wuhan, China, described a series of
unexplained pneumonias and shortly
thereafter identified the causative
agent as a novel coronavirus (named
Severe Acute Respiratory Syndrome
Coronavirus-2 [SARS-CoV-2]). It is
believed that SARS-CoV-2 entered the
human population from animals andGastroenterology 2020;159:6–13that the exposure may have been a live
food market in that province of China.
SARS-CoV-2 can result in a mild or
severe respiratory illness called
COVID-19. COVID-19 rapidly spread
throughout the world and on March
11, 2020, the World Health Organiza-
tion declared it a pandemic.1 At the
time of this writing, it has affected
>800,000 people worldwide, and
accounted for >38,700 deaths, and
these numbers continue to rise
sharply.2 COVID-19 has now been re-
ported to affect individuals of all ages,
with a slight predominance in men.
Mortality from COVID-19 is estimated
variably from 1.5% to as high as 3.0%,
with identified risk factors of older age
and comorbid illnesses including hy-
pertension, diabetes, and other car-
diovascular diseases. The risk of
COVID-19 or death from COVID-19 in
patients treated for immune-mediated
diseases is unknown at this time, but
it has been presumed that patients
who are immunosuppressed are at
higher risk for infection with SARS-
CoV-2 and may be at increased risk
for COVID-19.
IBD and COVID-19
Treatment of IBD is aimed at con-
trolling an overactive immune
response, and currently involves use of
a number of well-studied classes of
immune modifying therapies
(Supplementary Table 1). Many of
these treatments are associated with
known increased risks of infections, so
the IBD population has been consid-
ered an at-risk population for infection
with SARS-CoV-2. However, the actual
risks of infection or of development of
COVID-19 in patients with IBD are not
known, nor are the appropriate ad-
justments to treatments to mitigate
such risks or reduce complications
from the disease.The IOIBD Meeting on
COVID-19
The 2020 annual meeting for IOIBD
was scheduled to occur in March, but
was cancelled owing to the emergenceof COVID-19. Given how this disease
might affect patients with IBD and the
absence of data, members of the orga-
nization recognized the need for rapid
international collaboration and held 2
IBD-COVID-19 webinars, the details of
which are summarized in this
Commentary.
The overall goal of these webinars
was to develop a number of key
statements that could be used to guide
the management of patients with IBD
during this pandemic. Using RAND
panel methodology all IOIBD members
and selected content experts were
asked to participate in a survey before
the first webinar that included state-
ments related to risks of SARS-CoV-2
and COVID-19 in patients with IBD, as
well as statements related to disease
management under a variety of clinical
scenarios.
During the first webinar, held on
March 20, 2020, IOIBD members
shared their direct experiences with
COVID-19 in the epicenters of China
and Italy (Zhihua Ran and Silvio
Danese, respectively), followed by
information about the successful
population-wide response in Hong
Kong (Siew Ng). Also discussed was
the organization of international reg-
istries.3,4 At the time of this first
webinar, there were only 15 cases of
IBD and COVID-19 reported. Also
presented and discussed at length
were the possible effects of immuno-
therapies on infection in patients with
IBD (Maria Abreu, Markus Neurath),
which is summarize elsewhere in this
article. Next, the results from the first
round of voting were reviewed and
the group focused on statements in
which there was disagreement or
uncertainty.
Subsequent to this first webinar, as
per RAND panel protocol, a second
round of voting with modified state-
ments was sent to the participants.
These results led to the statements
summarized below and presented in
their entirety in Table 1. A second
webinar occurred on March 27, 2020,
to review results and to continue dis-






IOIBD used the established RAND/
UCLA method, which uses a Delphi panel
approach to address the appropriateness
of specific medical interventions or
medical decisions.5 We used a modified
RAND panel to allow for a rapid cycle of
2 rounds of voting by the expert panel.
The panel was presented a web-based
questionnaire that included clinical sce-
narios specific to patients with IBD dur-
ing the COVID-19 pandemic. The
questionnaire was created and iteratively
improved by 3 of the authors (DTR, MTA,
CAS) and then distributed electronically
to the respondents. The panelists
included the membership of IOIBD in
addition to other invited specialists in
IBD. Respondents rated each of the pa-
tient scenarios on a scale of 1–9, such
that statements rated 1–3 are considered
inappropriate, 4–6 are uncertain, and
7–9 are appropriate. After the first round
of anonymous voting, the first webinar
occurred and related content was
reviewed as summarized and the results
of the first round of voting were
reviewed. The subsequent discussion
focused on scenarios that had a median
in the uncertainty range and those with a
high standard deviation. The goal of the
discussion was to understand views of
the panel in preparation for a second
round of voting, not necessarily to ach-
ieve consensus. The second round ques-
tionnaire was nearly identical to the first,
except for clarifying a few of the original
scenarios and adding 2 additional sec-
tions that were not covered in round 1
(how to manage patients in IBD clinical
trials and when to restart medications if
they were being held for active COVID-
19 infection). Table 1 lists the state-
ments from the second round of voting.
The final appropriateness category is
based on the second round voting me-
dian. The mean, standard deviation, and
disagreement index (DI) were also








The DI expresses the spread of re-
sponses and is calculated using a previ-
ously described approach5 and the
following formula:
Using this formula, agreement is
defined as a DI of <1, whereas
disagreement is defined as a DI of 1.5
Summary of RAND Panel
and Development of
Guidance Statements
Of the 76 statements in the second-
round survey, 26 were rated as
appropriate, 19 as uncertain, and 31 as
inappropriate. Although agreement is
not required, there was agreement (DI
of <1) in 64 of 76 scenarios (84%).
 The panel agreed that having IBD
(either Crohn’s disease or ulcera-
tive colitis) did not increase the
risk of becoming infected with
SARS-CoV-2 or developing COVID-
19 and having an ostomy or J-
pouch did not increase the risk for
COVID-19.
 The panel agreed that it is safe to
continue to receive infusions in an
infusion center, assuming that the
infusion center has a SARS-CoV-2
screening protocol in place.
 The group was in agreement that it
is appropriate to reduce the dose
or discontinue prednisone to pre-
vent infection from SARS-CoV-2,
but voted that it was inappro-
priate to reduce the dose or stop
other IBD therapies to prevent
infection from SARS-CoV-2.
 There were mixed responses
related to the other clinical sce-
narios and therapies. The key
findings regarding the manage-
ment of medical therapy for IBD in
the setting of the COVID-19
pandemic are summarized in
Figure 1.




therapy of an anti-tumor necrosis
factor (TNF) and immune modu-
lator, the group was uncertain if
the immune modulator should be
dose reduced to potentially modify
the risk of infection with SARS-
CoV-2, but was in agreement and
did vote that it is appropriate to
discontinue the immune modu-
lator in a patient who is known to
be infected with SARS-CoV-2 or
when a patient develops COVID-
19.
 In the scenario of a patient who
stopped IBD medications because
either they tested positive for
SARS-CoV-2 infection or had
COVID-19, the group voted that it
is appropriate to restart their
medications if they do not develop
symptoms after 2 weeks, or when
symptoms have completely
resolved.
 The group was in agreement and
voted it was appropriate to post-
pone nonessential endoscopic
procedures.
 Furthermore, the panel voted that
patients in clinical trials should
continue those therapies unless
they become infected by SARS-
CoV-2 or develop COVID-19.
 The group voted that it was
appropriate to discontinue the
clinical trial drug if a patient tests
positive for SARS-CoV-2 or de-
velops COVID-19, but there was
some disagreement in the
responses.
The full results of the first survey
(before the webinar) and second sur-






Possible Effects of IBD
Therapies
It is now known that similar to the
2002 SARS-CoV, the 2019 SARS-CoV-2
requires the angiotensin-converting
enzyme 2 (ACE-2) receptor to enter7
Table 1.Final Assessment of Statements Related to Risk of Infection with SARS-CoV-2 or development of COVID-19 in
Patients with IBD by the IOIBD Panel (n ¼ 66 participants)
76 Statements Median SD Category DI
Risk of infection/disease
The risk of infection with SARS-CoV-2 is the same whether a patient has IBD or
does not have IBD.
8 1.7 Appropriate –0.71
Independent of treatment, patients with Crohn’s disease have a greater risk of
infection with SARS-CoV-2 than the general population.
2 1.7 Inappropriate 0.16
Independent of treatment, patients with ulcerative colitis have a greater risk of
infection with SARS-CoV-2 than the general population.
2 1.7 Inappropriate 0.16
Having active inflammation from IBD increases the risk of getting SARS-CoV-2. 5.5 1.8 Uncertain 0.63
Patients with IBD who are exposed to SARS-CoV-2 have a higher risk of developing
COVID-19 compared to patients without IBD.
5 1.7 Uncertain 0.52
Patients with IBD who have COVID-19 have a higher mortality compared to patients
without IBD.
3.5 1.7 Inappropriate 0.52
Patients with an ostomy are at increased risk for COVID-19. 2 1.2 Inappropriate 0.13
Patients with a J pouch are at increased risk for COVID-19. 2 1.2 Inappropriate 0.13
Elective surgeries and endoscopies should be postponed at this time. 8.5 1.6 Appropriate –0.34
Healthcare workers with IBD on immune modifying medications working in an
environment with known or suspected COVID-19 patients should continue
working, assuming they are following standard prevention methods.
5.5 2.0 Uncertain 2.02
Patients with IBD on immune-modifying medications should discontinue any
nonessential travel.
9 1.2 Appropriate –0.17
It is safe to continue infusions in an infusion center assuming the infusion center
has a screening protocol in place.
8 1.0 Appropriate –0.71
Therapy class: 5-ASA
5-ASA increases the risk of infection with SARS-CoV-2. 1 0.7 Inappropriate 0.00
5-ASA increases the risk of COVID-19. 1 0.7 Inappropriate 0.12
Patients taking 5-ASA therapy should reduce the dose of therapy to prevent SARS-
CoV-2 infection.
1 0.7 Inappropriate 0.00
Patients taking 5-ASA therapy should discontinue therapy to prevent SARS-CoV-2
infection.
1 0.7 Inappropriate 0.00
Patients taking 5-ASA therapy should stop therapy if they test positive for SARS-
CoV-2 but do not have COVID-19.
1 1.1 Inappropriate 0.00
Patients taking 5-ASA therapy should stop therapy if they develop COVID-19. 1 1.5 Inappropriate 0.13
Therapy class: oral budesonide
Budesonide increases the risk of infection with SARS-CoV-2. 3 1.4 Inappropriate 0.16
Budesonide increases the risk of COVID-19. 3 1.5 Inappropriate 0.22
Patients taking budesonide therapy should reduce the dose of therapy to prevent
SARS-CoV-2 infection.
3 1.8 Inappropriate 0.16
Patients taking budesonide therapy should discontinue therapy to prevent SARS-
CoV-2 infection.
2 1.6 Inappropriate 0.16
Patients taking budesonide therapy should stop therapy if they test positive for
SARS-CoV-2 but do not have COVID-19.
4 2.1 Uncertain 0.52
Patients taking budesonide therapy should stop therapy if they develop COVID-19. 5 2.2 Uncertain 0.85
Therapy class: oral prednisone (20 mg/d)
Prednisone (20 mg/d) increases the risk of infection with SARS-CoV-2. 7 2.1 Appropriate 2.35
Prednisone (20 mg/d) increases the risk of COVID-19. 7 2.0 Appropriate 10.00
Patients taking prednisone therapy (20 mg/d) should reduce the dose of therapy
to prevent SARS-CoV-2 infection.
7 2.0 Appropriate 0.00
Patients taking prednisone therapy (20 mg/d) should discontinue therapy (taper as
appropriate) to prevent SARS-CoV-2 infection.
7 2.3 Appropriate 2.35
Patients taking prednisone therapy (20 mg/d) should stop therapy (taper as
appropriate) if they test positive for SARS-CoV-2 but do not have COVID-19.
7 1.7 Appropriate –0.71
Patients taking prednisone therapy (20 mg/d) should stop therapy (taper as
appropriate) if they develop COVID-19.
8 1.6 Appropriate –0.71
Therapy class: thiopurines
Azathioprine/6-MP increases the risk of infection with SARS-CoV-2. 5 2.0 Uncertain 0.85
Azathioprine/6-MP increases the risk of COVID-19. 6 1.9 Uncertain 0.63
Patients taking azathioprine/6-MP should reduce the dose of therapy to prevent
SARS-CoV-2 infection.
3 2.1 Inappropriate 0.56
Patients taking azathioprine/6-MP should discontinue therapy to prevent SARS-
CoV-2 infection.
3 1.9 Inappropriate 0.35
Patients taking azathioprine/6-MP should stop therapy if they test positive for
SARS-CoV-2 but do not have COVID-19.




76 Statements Median SD Category DI
Patients taking azathioprine/6-MP should stop therapy if they develop COVID-19. 8 1.5 Appropriate –0.71
Therapy: methotrexate
Methotrexate increases the risk of infection with SARS-CoV-2. 4 1.7 Uncertain 0.52
Methotrexate increases the risk of COVID-19. 5 1.9 Uncertain 0.44
Patients taking methotrexate should reduce the dose of therapy to prevent SARS-
CoV-2 infection.
3 1.6 Inappropriate 0.16
Patients taking methotrexate should discontinue therapy to prevent SARS-CoV-2
infection.
3 1.5 Inappropriate 0.16
Patients taking methotrexate should stop therapy if they test positive for SARS-
CoV-2 but do not have COVID-19.
7 2.0 Appropriate 10.00
Patients taking methotrexate should stop therapy if they develop COVID-19. 7 1.6 Appropriate –0.71
Therapy class: anti-TNF
Anti-TNF therapy increases the risk of infection with SARS-CoV-2. 4 1.7 Uncertain 0.22
Anti-TNF therapy increases the risk of COVID-19. 4 1.7 Uncertain 0.52
Patients taking anti-TNF therapy should reduce the dose of therapy to prevent
SARS-CoV-2 infection.
2 1.4 Inappropriate 0.16
Patients taking anti-TNF therapy should discontinue therapy to prevent SARS-CoV-
2 infection.
2 1.2 Inappropriate 0.00
Patients taking anti-TNF therapy should stop therapy if they test positive for SARS-
CoV-2 but do not have COVID-19.
6 2.2 Uncertain 2.35
Patients taking anti-TNF therapy should stop therapy if they develop COVID-19. 7 2.0 Appropriate –0.71
Therapy: vedolizumab
Vedolizumab increases the risk of infection with SARS-CoV-2. 3 1.5 Inappropriate 0.16
Vedolizumab increases the risk of COVID-19. 3 1.6 Inappropriate 0.37
Patients taking vedolizumab should reduce the dose of therapy to prevent SARS-
CoV-2 infection.
2 1.3 Inappropriate 0.15
Patients taking vedolizumab should discontinue therapy to prevent SARS-CoV-2
infection.
2 1.2 Inappropriate 0.00
Patients taking vedolizumab should stop therapy if they test positive for SARS-
CoV-2 but do not have COVID-19.
5 2.2 Uncertain 0.85
Patients taking vedolizumab should stop therapy if they develop COVID-19. 6 2.1 Uncertain 2.35
Therapy: ustekinumab
Ustekinumab increases the risk of infection with SARS-CoV-2. 3 1.5 Inappropriate 0.16
Ustekinumab increases the risk of COVID-19. 3 1.6 Inappropriate 0.16
Patients taking ustekinumab should reduce the dose of therapy to prevent SARS-
CoV-2 infection.
2 1.1 Inappropriate 0.16
Patients taking ustekinumab should discontinue therapy to prevent SARS-CoV-2
infection.
2 1.1 Inappropriate 0.00
Patients taking ustekinumab should stop therapy if they test positive for SARS-
CoV-2 but do not have COVID-19.
6 2.1 Uncertain 2.35
Patients taking ustekinumab should stop therapy if they develop COVID-19. 7 2.1 Appropriate –1.57
Therapy: tofacitinib
Tofacitinib increases the risk of infection with SARS-CoV-2. 5 1.9 Uncertain 0.52
Tofacitinib increases the risk of COVID-19. 5 1.9 Uncertain 0.32
Patients taking tofacitinib should reduce the dose of therapy to prevent SARS-CoV-
2 infection.
3 1.9 Inappropriate 0.19
Patients taking tofacitinib should discontinue therapy to prevent SARS-CoV-2
infection.
3 1.5 Inappropriate 0.16
Patients taking tofacitinib should stop therapy if they test positive for SARS-CoV-2
but do not have COVID-19.
7 1.9 Appropriate 10.00
Patients taking tofacitinib should stop therapy if they develop COVID-19. 8 1.6 Appropriate –0.71
Combination therapy
Patients taking combination therapy with an anti-TNF and thiopurine/methotrexate
should reduce the dose of the thiopurine/methotrexate to prevent infection from
SARS-CoV-2.
4 2.2 Uncertain 0.91
Patients taking combination therapy with an anti-TNF and thiopurine/methotrexate
should stop the thiopurine/methotrexate if they test positive for SARS-CoV-2
but do not have COVID-19.
7 2.2 Appropriate –3.30
Patients taking combination therapy with an anti-TNF and thiopurine/methotrexate
should stop the thiopurine/methotrexate if they develop COVID-19.
8 1.3 Appropriate 0.00
Clinical trials
Patients taking clinical trial drugs should discontinue therapy to prevent SARS-
CoV-2 infection.
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Patients taking clinical trial drugs should stop therapy if they test positive for SARS-
CoV-2 but do not have COVID-19.
7 1.9 Appropriate 10.00
Patients taking clinical trial drugs should stop therapy if they develop COVID-19. 8 1.6 Appropriate –0.32
Approach to active disease
A patient with moderately to severely active Crohn’s disease or ulcerative colitis
(new diagnosis or relapsing disease) should be treated with the same therapies
you would choose in the pre-COVID-19 era.
7 2.1 Appropriate 10.00
Treatment of IBD after SARS-coV-2 infection or COVID-19
In an IBD patient who tests positive for SARS-CoV-2 and whose IBD meds have
been stopped because of this, IBD meds can be restarted after 14 days
(provided they have not developed COVID-19).
7 1.5 Appropriate –0.71
In an IBD patient who develops COVID-19 and whose IBD meds have been
stopped, IBD meds can be restarted after COVID-19 symptoms resolve.
7 1.9 Appropriate 10.00
In an IBD patient who develops COVID-19 and whose IBD meds have been
stopped, IBD meds can be restarted after 2 nasopharyngeal PCR tests are
negative.
8 1.6 Appropriate –0.71
5-ASA, 5-aminosalicylic acid; 6-MP, mercaptopurine; COVID-19, coronavirus disease 2019; DI, disagreement index; IBD,
inflammatory bowel disease; IOIBD, International Organization for the Study of Inflammatory Bowel Diseases; SARS-CoV-2,
severe acute respiratory syndrome-coronavirus-2; SD, standard deviation; TNF, tumor necrosis factor.
COMMENTARIESthe cell as well as TMPRSS2, a serine
protease that cleaves the viral spike to
permit viral entry.6 The ACE-2 recep-
tor is found at high levels in alveolar
type-2 cells in the lung. However,
important for IBD, the small intestine
is also known to express ACE-2; in a
patient who was infected with SARS-
CoV-2, ACE-2 and the virus were
found in stomach, duodenal, and rectal
biopsies.7 Moreover, single cell tran-
scriptomics of the gut corroborate that
ACE-2 is expressed in the gastrointes-
tinal tract.8 The virus has also been
found in the stool of infected patients
for longer periods of time than in
sputum, although in smaller amounts.9
ACE-2 can be up-regulated after
infection with SARS-CoV and Middle
Eastern Respiratory Syndrome
(MERS)-CoV–related viruses, suggest-
ing there is a positive feed forward
loop once patients are infected with
virus. In vitro, IFN-g can induce ACE-2
and the promoter region of ACE-2
contains several immune and cytokine
responsive transcription factor binding
sites, suggesting that inflammation
may increase expression of ACE-2.8
The other important factor for viral
entry is endocytosis. Baricitinib is a
JAK1, JAK2 and TYK2 inhibitor
currently available for rheumatoid
arthritis and in clinical development
for IBD and it may inhibit endocy-
tosis.10 This effect does not occur with10the less selective JAK inhibitor,
tofacitinib.
Early in the disease course for
SARS-CoV and MERS-CoV, the innate
immune response to the virus through
interferon and interferon-stimulated
genes may limit viral replication, but
is also subverted by the virus itself.11
In later stages, the cytokine release
syndrome, characterized by high levels
of proinflammatory cytokines such as
IL-6, has been suggested to trigger
acute respiratory distress syndrome in
SARS-CoV-2 infections and lead to fatal
outcomes. In terms of the therapies we
use for IBD and the potential effect on
SARS-CoV2, previous experience with
high-dose steroids as a treatment for
SARS-CoV or MERS-CoV was not
effective and delayed viral clearance.12
Therefore, steroids are not recom-
mended as a treatment for SARS-CoV-
2, but the doses that were used in
these studies are much higher than the
doses that are used in IBD.12 With
respect to thiopurines, mercaptopurine
and 6-thioguanine have potential anti-
viral activity against MERS and SARS,
at least in vitro.13 There are no publi-
cations, however, showing that this
finding was tested in patients. The
other issue that has to be considered in
the context of thiopurines is lympho-
penia, because patients on thiopurines
may develop lymphopenia from the
drug. Unfortunately, patients withlymphopenia caused by SARS-CoV-2
have a worse prognosis and have an
increased risk of death associated with
the virus.14,15 At the current time,
there are no specific data available on
methotrexate and COVID-19, but in
theory the pulmonary toxicity of
methotrexate may be of interest in the
setting of a virus that involves the
respiratory tract.
Many patients with IBD are using
monotherapy with biologics or the
novel small molecule Janus kinase in-
hibitor, tofacitinib. Anti-TNF therapy
may impact viral immunity given that
there is a small increased risk of her-
pes zoster and hepatitis B virus reac-
tivation. Although high IL-2R and IL-6
serum levels have been associated with
severe COVID-19 cases, no effect on
TNF levels was noted.16 IFN-g and TNF
production by CD4þ T cells have been
associated with severe SARS-CoV and,
therefore, inhibition of TNF has been
proposed as a treatment of the cyto-
kine release syndrome that can occur
in some of these patients.17,18
Vedolizumab primarily inhibits a-4,
b-7 lymphocyte homing of Th17 and
Th9 cells as well as regulatory T cells
to the intestine. Viral infections are
rare with vedolizumab therapy.19 In
patients who had concurrent hepatitis
B or C virus infection, there was no
viral reactivation and there was sus-
tained virologic control in simian
Figure 1.Final results of the RAND appropriateness panel for the use of medica-
tions to treat IBD in the setting of SARS-CoV-2 or COVID-19. 5-ASA, 5-
aminosalicylate; 6MP, 6-mercaptopurine; AZA, azathioprine; anti-TNF, anti-tumor
necrosis factor; Bud, budesonide; COVID-19, coronavirus disease; IBD, inflam-
matory bowel disease; MTX, methotrexate; Pred, prednisone; SARS-CoV-2, severe
acute respiratory syndrome-coronavirus-2; TOFA, tofacitinib; UST, ustekinumab;
VEDO, vedolizumab.
COMMENTARIESimmunodeficiency–infected macaques
after antiretroviral and vedolizumab
therapy.20 Vedolizumab has been used
for clinical therapy in patients with
IBD and early clinical trials in HIV have
not shown effects on viral load.21 With
respect to ustekinumab, this agent can
prevent Th1þ T-cell priming and IFN-g
production by CD4þ T cells and sup-
press Th17þ T-cell activation and
cytokine production. There has been
no increase in viral infections in IBD or
psoriasis patients receiving ustekinu-
mab in large postmarketing regis-
tries.22 Tocilizumab, an anti–IL-6R
antibody, is currently being tested in
patients with severe COVID-19 and
may decrease the severity of acute
respiratory distress syndrome.23,24
Finally, tofacitinib has been associated
with a clear increase in reactivation of
herpes zoster. Thus, tofacitinib might
inhibit viral immunity; in contrast, it
might help with the severe inflamma-
tory response that ultimately leads to
death. In certain studies, tofacitinib can
inhibit interferon secretion.
When considering the management
of IBD medications, one must also take
into account the half-life of the drugs.
In general, 5.5 half-lives are required
to achieve very low levels of drug.
Corticosteroids have a half-life of about
24 hours, but it is dose dependent and
the higher the dose, the longer the
biological effect. Thiopurines havebeen studied in patients with IBD and
the median 6-thioguanine elimination
half-life is 6.8 days with very low levels
of 6-thioguanine present by 40 days.25
Studies of vaccine responses in pa-
tients on thiopurines demonstrate that
patients were able to mount normal
immune responses.26 Methotrexate has
a 6-hour half-life and takes <3 days to
eliminate. Tofacitinib has a half-life of
between 3 and 6 hours, depending on
whether it is an immediate- or
extended-release formulation.27
Studies in normal volunteers treated
with tofacitinib, however, found de-
fects in immune function for 1 month
after drug withdrawal.28 For the sub-
cutaneous and IV-based biologics, the
half-life is much longer. The half-life of
adalimumab is between 10 and 20
days and the half-life of infliximab is
between is 7 and 12 days. The median
half-life for ustekinumab is approxi-
mately 19 days in patients with
Crohn’s disease, and the serum half-life
of vedolizumab is 25 days. Thus, even
after cessation of these immune ther-
apies, there may be continued effects
on the patient and implications for the
infection.Summary and Next Steps
This meeting was convened by an
international group of IBD physician-
scientists to develop guidance for themanagement of patients with IBD
during the COVID-19 pandemic. Using
a RAND panel methodology, the
group developed a series of state-
ments regarding the risk of infection
and management of therapies that
will assist patients and healthcare
providers during this uncertain time.
These statements are based on expert
opinion in the absence of definitive
data or, in some cases, any data. They
are meant to help inform clinical de-
cision making, but should not replace
individualized management de-
cisions. The IOIBD and the invited
experts are participating in weekly
updates of this rapidly evolving situ-
ation and will update this informa-
tion for patients and colleagues as
appropriate.
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Supplementary Table 1.Types of IBD Therapies Assessed by the IOIBD Panel
Therapy type Also known as
5-Aminosalicylic acid (5-ASA) Asacol, Apriso, balsalazide, Dezicol, Lialda, mesalamine, mesalazine, Pentasa
Oral budesonide Entocort, Uceris
Steroids (the dose discussed is
oral prednisone and 20 mg/d)
Prednisone, Medrol, Hydrocortisone
Thiopurines 6-Mercaptopurine, azathioprine, Azasan, Purinethol
Methotrexate Trexal, Rheumatrex
JAK inhibitor Tofacitinib (Xeljanz)
Anti-TNF Adalimumab (Humira, Abrilada, Ajevita, Cyltezo, Hyrimoz, Hadlima), certolizumab pegol (Cimzia),
golimumab (Simponi), infliximab (Remicade, Avsola, Inflectra, Ixifi Remsima, Renflexis)
Anti-IL12/23 Ustekinumab (Stelara)
Anti-integrin Vedolizumab (Entyvio), (the panel did not discuss natalizumab (Tysabri)




Supplementary Table 2.Full Results of Assessment of Statements Related to Risk of Infection with SARS-CoV-2 or
Development of COVID-19 in Patients with IBD by the IOIBD Panel
Statements
First RAND Panel Voting
Second RAND Panel Voting After
20 March 2020 Webinar
(n ¼ 64 participants, 69 statements) (n ¼ 66 participants, 76 statements)
Median SD Category DI Median SD Category DI
Risk of infection/disease
The risk of infection with SARS-CoV-2
is the same whether a patient has
IBD or does not have IBD.
7 1.9 Appropriate 2.35 8 1.7 Appropriate –0.71
Independent of treatment, patients
with Crohn’s disease have a
greater risk of infection with SARS-
CoV-2 than the general population.
3 1.8 Inappropriate 0.55 2 1.7 Inappropriate 0.16
Independent of treatment, patients
with ulcerative colitis have a
greater risk of infection with SARS-
CoV-2 than the general population.
3 1.8 Inappropriate 0.65 2 1.7 Inappropriate 0.16
Having active inflammation from IBD
increases the risk of getting SARS-
CoV-2.
5 1.9 Uncertain 0.69 5.5 1.8 Uncertain 0.63
Patients with IBD who are exposed to
SARS-CoV-2 have a higher risk of
developing COVID-19 compared to
patients without IBD.
5 1.9 Uncertain 0.37 5 1.7 Uncertain 0.52
Patients with IBD who have COVID-19
have a higher mortality compared
to patients without IBD.
4 1.7 Uncertain 0.52 3.5 1.7 Inappropriate 0.52
Patients with an ostomy are at
increased risk for COVID-19.
3 1.8 Inappropriate 0.16 2 1.2 Inappropriate 0.13
Patients with a J pouch are at
increased risk for COVID-19.
3 1.8 Inappropriate 0.16 2 1.2 Inappropriate 0.13
Elective surgeries and endoscopies
should be postponed at this time.
8 2.0 Appropriate -0.44 8.5 1.6 Appropriate –0.34
Healthcare workers with IBD on immune
modifying medications working in an
environment with known or
suspected COVID-19 patients should
continue working, assuming they are
following standard prevention
methods.
6 2.2 Uncertain 2.35 5.5 2.0 Uncertain 2.02




9 1.5 Appropriate 0.00 9 1.2 Appropriate –0.17
It is safe to continue infusions in an
infusion center assuming the
infusion center has a screening
protocol in place.
8 1.3 Appropriate -0.71 8 1.0 Appropriate –0.71
Therapy class: 5-ASA
5-ASA increases the risk of infection
with SARS-CoV-2.
1 1.2 Inappropriate 0.13 1 0.7 Inappropriate 0.00
5-ASA increases the risk of COVID-19. 1 1.2 Inappropriate 0.13 1 0.7 Inappropriate 0.12
Patients taking 5-ASA therapy should
reduce the dose of therapy to
prevent SARS-CoV-2 infection.
1 0.8 Inappropriate 0.13 1 0.7 Inappropriate 0.00
Patients taking 5-ASA therapy should
discontinue therapy to prevent
SARS-CoV-2 infection.
1 0.9 Inappropriate 0.00 1 0.7 Inappropriate 0.00
Patients taking 5-ASA therapy should
stop therapy if they test positive for
SARS-CoV-2 but do not have
COVID-19.





First RAND Panel Voting
Second RAND Panel Voting After
20 March 2020 Webinar
(n ¼ 64 participants, 69 statements) (n ¼ 66 participants, 76 statements)
Median SD Category DI Median SD Category DI
Patients taking 5-ASA therapy should
stop therapy if they develop
COVID-19.
1 1.4 Inappropriate 0.13 1 1.5 Inappropriate 0.13
Therapy class: oral budesonide
Budesonide increases the risk of
infection with SARS-CoV-2.
3 1.8 Inappropriate 0.63 3 1.4 Inappropriate 0.16
Budesonide increases the risk of
COVID-19.
4 1.7 Uncertain 0.52 3 1.5 Inappropriate 0.22
Patients taking budesonide therapy
should reduce the dose of therapy
to prevent SARS-CoV-2 infection.
3 2.0 Inappropriate 0.52 3 1.8 Inappropriate 0.16
Patients taking budesonide therapy
should discontinue therapy to
prevent SARS-CoV-2 infection.
3 1.7 Inappropriate 0.31 2 1.6 Inappropriate 0.16
Patients taking budesonide therapy
should stop therapy if they test
positive for SARS-CoV-2 but do
not have COVID-19.
4 2.1 Uncertain 0.52 4 2.1 Uncertain 0.52
Patients taking budesonide therapy
should stop therapy if they develop
COVID-19.
5 2.4 Uncertain 1.76 5 2.2 Uncertain 0.85
Therapy class: oral prednisone (20 mg/d)
Prednisone (20 mg/d) increases the
risk of infection with SARS-CoV-2.
7 1.9 Appropriate 10.00 7 2.1 Appropriate 2.35
Prednisone (20 mg/d) increases the
risk of COVID-19.
7 1.4 Appropriate 0.00 7 2.0 Appropriate 10.00
Patients taking prednisone therapy
(20 mg/d) should reduce the dose
of therapy to prevent SARS-CoV-2
infection.
7 2.0 Appropriate 10.00 7 2.0 Appropriate 0.00
Patients taking prednisone therapy
(20 mg/d) should discontinue
therapy (taper as appropriate) to
prevent SARS-CoV-2 infection.
5 2.0 Uncertain 0.85 7 2.3 Appropriate 2.35
Patients taking prednisone therapy
(20 mg/d) should stop therapy
(taper as appropriate) if they test
positive for SARS-CoV-2 but do
not have COVID-19.
6 2.1 Uncertain 2.35 7 1.7 Appropriate –0.71
Patients taking prednisone therapy
(20 mg/d) should stop therapy
(taper as appropriate) if they
develop COVID-19.
7 2.3 Appropriate -4.49 8 1.6 Appropriate –0.71
Therapy class: thiopurines
Azathioprine/6-MP increases the risk
of infection with SARS-CoV-2.
6 1.9 Uncertain 0.63 5 2.0 Uncertain 0.85
Azathioprine/6-MP increases the risk
of COVID-19.
6 1.7 Uncertain 2.35 6 1.9 Uncertain 0.63
Patients taking azathioprine/6-MP
should reduce the dose of therapy to
prevent SARS-CoV-2 infection.
3 1.9 Inappropriate 0.52 3 2.1 Inappropriate 0.56
Patients taking azathioprine/6-MP
should discontinue therapy to
prevent SARS-CoV-2 infection.





First RAND Panel Voting
Second RAND Panel Voting After
20 March 2020 Webinar
(n ¼ 64 participants, 69 statements) (n ¼ 66 participants, 76 statements)
Median SD Category DI Median SD Category DI
Patients taking azathioprine/6-MP
should stop therapy if they test
positive for SARS-CoV-2 but do
not have COVID-19.
7 2.3 Appropriate 2.35 7 2.0 Appropriate –2.32
Patients taking azathioprine/6-MP
should stop therapy if they develop
COVID-19.
8 2.0 Appropriate -0.71 8 1.5 Appropriate –0.71
Therapy: methotrexate
Methotrexate increases the risk of
infection with SARS-CoV-2.
5 1.9 Uncertain 0.92 4 1.7 Uncertain 0.52
Methotrexate increases the risk of
COVID-19.
5 1.7 Uncertain 0.85 5 1.9 Uncertain 0.44
Patients taking methotrexate should
reduce the dose of therapy to
prevent SARS-CoV-2 infection.
3 1.9 Inappropriate 0.52 3 1.6 Inappropriate 0.16
Patients taking methotrexate should
discontinue therapy to prevent
SARS-CoV-2 infection.
3 2.1 Inappropriate 0.57 3 1.5 Inappropriate 0.16
Patients taking methotrexate should
stop therapy if they test positive for
SARS-CoV-2 but do not have
COVID-19.
6.5 2.2 Appropriate 2.35 7 2.0 Appropriate 10.00
Patients taking methotrexate should
stop therapy if they develop
COVID-19.
7 2.2 Appropriate -0.71 7 1.6 Appropriate –0.71
Therapy class: anti-TNFs
Anti-TNF therapy increases the risk of
infection with SARS-CoV-2.
3 1.9 Inappropriate 0.52 4 1.7 Uncertain 0.22
Anti-TNF therapy increases the risk of
COVID-19.
5 2.1 Uncertain 0.52 4 1.7 Uncertain 0.52
Patients taking anti-TNF therapy
should reduce the dose of therapy
to prevent SARS-CoV-2 infection.
3 1.6 Inappropriate 0.16 2 1.4 Inappropriate 0.16
Patients taking anti-TNF therapy
should discontinue therapy to
prevent SARS-CoV-2 infection.
2 1.8 Inappropriate 0.16 2 1.2 Inappropriate 0.00
Patients taking anti-TNF therapy
should stop therapy if they test
positive for SARS-CoV-2 but do
not have COVID-19.
5 2.4 Uncertain 0.85 6 2.2 Uncertain 2.35
Patients taking anti-TNF therapy
should stop therapy if they develop
COVID-19.
7 2.5 Appropriate 30.00 7 2.0 Appropriate –0.71
Therapy: vedolizumab
Vedolizumab increases the risk of
infection with SARS-CoV-2.
3 2.0 Inappropriate 0.65 3 1.5 Inappropriate 0.16
Vedolizumab increases the risk of
COVID-19.
4 2.0 Uncertain 0.65 3 1.6 Inappropriate 0.37
Patients taking vedolizumab should
reduce the dose of therapy to
prevent SARS-CoV-2 infection.
2 1.7 Inappropriate 0.22 2 1.3 Inappropriate 0.15
Patients taking vedolizumab should
discontinue therapy to prevent
SARS-CoV-2 infection.





First RAND Panel Voting
Second RAND Panel Voting After
20 March 2020 Webinar
(n ¼ 64 participants, 69 statements) (n ¼ 66 participants, 76 statements)
Median SD Category DI Median SD Category DI
Patients taking vedolizumab should
stop therapy if they test positive for
SARS-CoV-2 but do not have
COVID-19.
4 2.4 Uncertain 0.92 5 2.2 Uncertain 0.85
Patients taking vedolizumab should
stop therapy if they develop
COVID-19.
5 2.6 Uncertain 1.77 6 2.1 Uncertain 2.35
Therapy: ustekinumab
Ustekinumab increases the risk of
infection with SARS-CoV-2.
3 1.7 Inappropriate 0.22 3 1.5 Inappropriate 0.16
Ustekinumab increases the risk of
COVID-19.
3 1.9 Inappropriate 0.52 3 1.6 Inappropriate 0.16
Patients taking ustekinumab should
reduce the dose of therapy to
prevent SARS-CoV-2 infection.
2 1.6 Inappropriate 0.16 2 1.1 Inappropriate 0.16
Patients taking ustekinumab should
discontinue therapy to prevent
SARS-CoV-2 infection.
2 1.6 Inappropriate 0.16 2 1.1 Inappropriate 0.00
Patients taking ustekinumab should
stop therapy if they test positive for
SARS-CoV-2 but do not have
COVID-19.
5 2.2 Uncertain 0.92 6 2.1 Uncertain 2.35
Patients taking ustekinumab should
stop therapy if they develop
COVID-19.
6 2.4 Uncertain 18.25 7 2.1 Appropriate –1.57
Therapy: tofacitinib
Tofacitinib increases the risk of
infection with SARS-CoV-2.
6 2.2 Uncertain 0.63 5 1.9 Uncertain 0.52
Tofacitinib increases the risk of
COVID-19.
6 2.1 Uncertain 2.35 5 1.9 Uncertain 0.32
Patients taking tofacitinib should
reduce the dose of therapy to
prevent SARS-CoV-2 infection.
3 2.4 Inappropriate 0.52 3 1.9 Inappropriate 0.19
Patients taking tofacitinib should
discontinue therapy to prevent
SARS-CoV-2 infection.
3 2.1 Inappropriate 0.60 3 1.5 Inappropriate 0.16
Patients taking tofacitinib should stop
therapy if they test positive for
SARS-CoV-2 but do not have
COVID-19.
6 2.4 Uncertain 2.35 7 1.9 Appropriate 10.00
Patients taking tofacitinib should stop
therapy if they develop COVID-19.
7 2.3 Appropriate -3.08 8 1.6 Appropriate –0.71
Combination therapy of anti-TNF and immunomodulator
Patients taking combination therapy
with an anti-TNF and thiopurine/
methotrexate should reduce the
dose of the thiopurine/
methotrexate to prevent infection
from SARS-CoV-2.
5 2.4 Uncertain 0.97 4 2.2 Uncertain 0.91
Patients taking combination therapy
with an anti-TNF and thiopurine/
methotrexate should stop the
thiopurine/methotrexate if they test
positive for SARS-CoV-2 but do
not have COVID-19.





First RAND Panel Voting
Second RAND Panel Voting After
20 March 2020 Webinar
(n ¼ 64 participants, 69 statements) (n ¼ 66 participants, 76 statements)
Median SD Category DI Median SD Category DI
Patients taking combination therapy
with an anti-TNF and thiopurine/
methotrexate should stop the
thiopurine/methotrexate if they
develop COVID-19.
8 2.2 Appropriate -0.93 8 1.3 Appropriate 0.00
Clinical trials
Patients taking clinical trial drugs
should discontinue therapy to
prevent SARS-CoV-2 infection.
2 1.4 Inappropriate 0.16
Patients taking clinical trial drugs
should stop therapy if they test
positive for SARS-CoV-2 but do
not have COVID-19.
7 1.9 Appropriate 10.00
Patients taking clinical trial drugs
should stop therapy if they develop
COVID-19.
8 1.6 Appropriate –0.32
Approach to active disease
A patient with moderately to severely
active Crohn’s disease or
ulcerative colitis (new diagnosis or
relapsing disease) should be
treated with the same therapies
you would choose in the pre-
COVID-19 era.
7 2.1 Appropriate 10.00
Treatment of IBD after SARS-CoV-2 infection or COVID-19
In an IBD patient who tests positive for
SARS-CoV-2 and whose IBD meds
have been stopped because of
this, IBD meds can be restarted
after 14 days (provided they have
not developed COVID-19).
7 1.5 Appropriate –0.71
In an IBD patient who develops
COVID-19 and whose IBD meds
have been stopped, IBD meds can
be restarted after COVID-19
symptoms resolve.
7 1.9 Appropriate 10.00
In an IBD patient who develops
COVID-19 and whose IBD meds
have been stopped, IBD meds can
be restarted after 2
nasopharyngeal PCR tests are
negative.
8 1.6 Appropriate –0.71
5-ASA, 5-aminosalicylic acid; 6-MP, mercaptopurine; COVID-19, coronavirus disease 2019; DI, disagreement index; IBD,
inflammatory bowel disease; IOIBD, International Organization for the Study of Inflammatory Bowel Diseases; SARS-CoV-2,
severe acute respiratory syndrome-coronavirus-2; SD, standard deviation; TNF, tumor necrosis factor.
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